Department of Defense (DoD) Peer Reviewed Medical Research Program Announcement

March 12, 2020Posted in: Research

The FY20 Defense Appropriations Act provides funding to the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP) to support to support medical research projects of clear scientific merit and direct relevance to military health.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). Topic areas and due dates vary.   A pre-application is mandatory for all programs. For specific information on these funding opportunities, please go to the website.  If you are interested in applying for any of these funding opportunities, please contact the Office of Sponsored Research and Programs.

Discovery Award – Letter of Intent due April 16, 2020

Postdoctoral fellow or clinical fellow (or equivalent) and above

  • Supports the exploration of a highly innovative new concept or untested theory.
  • Not intended to support the logical progression of an already established line of questioning.
  • Clinical trials will not be funded.
  • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
·      Maximum of $200,000 for direct costs (plus indirect costs)

·      Maximum period of performance is 2 years

 

Focused Program Award – Preproposal due April 23, 2020

Full Professor level or above (or equivalent)

  • Preproposal submission is required; application submission is by invitation only.
  • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
  • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
  • Projects may range from exploratory/
    hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
  • Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
·      Maximum of $7.2 million for direct costs (plus indirect costs)

·      Maximum period of performance is 4 years

 

Investigator-Initiated Research Award – Preproposal due April 23, 2020

Assistant Professor level or above (or equivalent)

  • Preproposal submission is required; application submission is by invitation only.
  • Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
  • Partnering PI Option available.
  • Clinical trials will not be funded.
·      Maximum of $1.6 million for direct costs (plus indirect costs)

·      Maximum of $2 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
  • Maximum period of performance is 4 years

 

Technology/ Therapeutic Development Award – Preproposal due April 23, 2020

Assistant Professor level or above (or equivalent)

  • Preproposal submission is required; application submission is by invitation only.
  • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
  • Product-oriented (e.g., device, drug, clinical guidelines).  The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
  • Clinical trials will not be funded.
·      Maximum of $4 million for direct costs (plus indirect costs

·      Maximum period of performance is 4 years
Tags: ,